about
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheuma...
Read More
86.25
0.65
(0.76%)
1.9M
XNAS Volume
XNAS 10 Sep, 2025 5:30 PM (EDT)
High Financial Strength
Mid Valuation
Technically Moderately Bullish
Strong Performer, Getting Expensive
These stocks are strong in quality and technical aspects but with medium valuation. Due to expensive valuation it is suggested that opportunity to be observed before buying.
View Similar
Embed DVM
Incyte Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..